XML 40 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Reporting | 3 Months Ended
--- | ---
Mar. 31, 2026
Segment Reporting [Abstract] |
Segment Reporting | Note 16. Segment Reporting We determine operating segments based on metrics that our Chief Operating Decision Makers (“CODM”) review internally to manage our business, including resource allocation and performance assessment. In August 2025, as a result of the new treasury policy, management re-evaluated the segment reporting structure and determined that the Company operates in two reportable segments other than our corporate activities. Our CODM regularly review financial results based on the two operating segments consisting of Medical Device and Digital Commodity Treasury. Medical Device: This segment is responsible for executing and managing the Company’s medical device sales and distribution business. Digital Commodity Treasury: This segment is responsible for executing and managing the Company’s treasury platform. The CODM uses segment operating income (loss) to evaluate operating segment performance and allocate resources. We do not prepare separate balance sheets by operating segment for the CODM, as assets are not evaluated as part of operating segment performance and resource allocation. We provide the CODM depreciation and amortization expense and impairment charges that are generated from operating segment-specific assets, as these are included in segment net (loss). The accounting policies for the segment information are the same as described in Note 2 - Summary of Significant Accounting Transactions. Transactions between segments are reported as if each were a stand-alone business and are eliminated in consolidation. The Company ceased manufacturing operations in October 2025. Accordingly, for the three months ended March 31, 2026 no medical device segment expenses were included as part of discontinued operations. Certain payroll and consultant expenses were allocated among segments on the basis of the estimated percentage of time spent on each segment. The following table presents the Company’s segment results (unaudited) for the three months ended March 31, 2026 and 2025: Schedule of Company’s Segment
|  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Corporate |  |  | Consolidated |
|  | THREE MONTHS ENDED MARCH 31, 2026 |  |  | THREE MONTHS ENDED MARCH 31, 2025 |
|  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Corporate |  |  | Consolidated |
Net Revenue |  | $ | 192,780 |  |  | $ | - |  |  | $ | - |  |  | $ | 192,780 |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Cost of goods sold |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | - |
Total Cost of Goods Sold |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | 202,578 |  |  |  | - |  |  |  | - |  |  |  | - |
Gross Margin (Loss) |  |  | (9,798 | ) |  |  | - |  |  |  | - |  |  |  | (9,798 | ) |  |  | - |  |  |  | - |  |  |  | - |
Staking revenue, net |  |  | - |  |  |  | 3,134,109 |  |  |  | - |  |  |  | 3,134,109 |  |  |  | - |  |  |  | - |  |  |  | - |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting fees – related parties |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  |  |  |  |  | - |
Selling, general and administrative |  |  | 175,488 |  |  |  | 438,209 |  |  |  | 4,439,622 |  |  |  | 5,053,320 |  |  |  | 427,082 |  |  |  | 937,214 |  |  |  | 1,364,296 |
Research and development |  |  | - |  |  |  | - |  |  |  | 137,097 |  |  |  | 137,097 |  |  |  | - |  |  |  | - |  |  |  | - |
Unrealized loss on digital commodities |  |  | - |  |  |  | 70,846,202 |  |  |  | - |  |  |  | 70,846,202 |  |  |  | - |  |  |  | - |  |  |  | - |
Realized loss on digital commodities |  |  | - |  |  |  | 10,789,841 |  |  |  | - |  |  |  | 10,789,841 |  |  |  | - |  |  |  | - |  |  |  | - |
Digital commodity transaction expenses |  |  | - |  |  |  | 63,821 |  |  |  | - |  |  |  | 63,821 |  |  |  | - |  |  |  | - |  |  |  | - |
Total Operating Expenses |  |  | 175,488 |  |  |  | 84,638,073 |  |  |  | 4,576,719 |  |  |  | 89,390,281 |  |  |  | 427,082 |  |  |  | 937,214 |  |  |  | 1,364,296 |
Loss from Operations |  |  | (185,286 | ) |  |  | (81,503,964 | ) |  |  | (4,576,719 | ) |  |  | (86,265,970 | ) |  |  | (427,082 | ) |  |  | (937,214 | ) |  |  | (1,364,296 | )
Other Income (Expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  | - |  |  |  | (19,229 | ) |  |  | 29,267 |  |  |  | 10,038 |  |  |  | - |  |  |  | (626,991 | ) |  |  | (626,991 | )
Fair market value adjustment on warrants |  |  | - |  |  |  | - |  |  |  | 16,708 |  |  |  | 16,708 |  |  |  | - |  |  |  | 4,618,889 |  |  |  | 4,618,889 |
Foreign currency loss |  |  | - |  |  |  | - |  |  |  | (8 | ) |  |  | (8 | ) |  |  | - |  |  |  | - |  |  |  | - |
Other Income (Expense), net |  |  | - |  |  |  | (19,229 | ) |  |  | 45,967 |  |  |  | 26,738 |  |  |  | - |  |  |  | 3,991,898 |  |  |  | 3,991,898 |
Income (Loss) Before Provision for Taxes |  |  | (185,286 | ) |  |  | (81,523,193 | ) |  |  | (4,530,752 | ) |  |  | (86,239,232 | ) |  |  | (427,082 | ) |  |  | 3,054,684 |  |  |  | 2,627,602 |
Tax Provision |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |  |  |  | - |
Income (Loss) from Continuing Operations |  |  | (185,286 | ) |  |  | (81,523,193 | ) |  |  | (4,530,752 | ) |  |  | (86,239,232 | ) |  |  | (427,082 | ) |  |  | 3,054,684 |  |  |  | 2,627,602 |
Discontinued Operations: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss from discontinued operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (830,769 | ) |  |  | - |  |  |  | (830,769 | )
Income tax benefit |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 132,000 |  |  |  | - |  |  |  | 132,000 |
Loss from Discontinued Operations |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (698,769 | ) |  |  | - |  |  |  | (698,769 | )
Net Income (Loss) |  | $ | (185,286 | ) |  | $ | (81,523,193 | ) |  | $ | (4,530,752 | ) |  | $ | (86,239,232 | ) |  | $ | (1,125,851 | ) |  | $ | 3,054,684 |  |  | $ | 1,928,833 |
The following table presents the total assets by segment (unaudited) at March 31, 2026 and December 31, 2025:
MARCH 31, 2026 |  |  | DECEMBER 31, 2025 |
Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |  |  | Medical Device |  |  | Digital Commodities |  |  | Corporate |  |  | Consolidated |
$ | 516,543 |  |  | $ | 174,476,910 |  |  | $ | 6,009,157 |  |  | $ | 181,002,610 |  |  | $ | 849,388 |  |  | $ | 257,253,661 |  |  | $ | 10,972,124 |  |  | $ | 269,075,173 |
Note: Net Loss by Segment includes Corporate, although not a reportable segment, only for reconciliation to the condensed consolidated statement of operations.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for segment reporting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 18: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 22: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration